Bladder Cancer Flashcards
Post TURBT Algorithm NMIBC
Genetic predisposition to NMIBC:
GSTM-1 and NAT-2
The most-studied genes associated with BlCa are N-acetyltransferase 2 and a deletion of glutathione S-transferase µ. Both of these genes are associated with the ability to metabolize aromatic amines and thus play an important role in the subset of individuals with environmental carcinogen exposure.
MSH2 (Lynch Syndrome)
Mismatch repair gene
LOH of ch. 9p, homozygous deletion of CDKN2A and loss of expression of p16
CIS → TP53, RB1, PTEN, oncogenes…
Bladder cancer T staging:
Ta: non-invasive papillary
Tis: CIS
T1: invades lamina propria
T2: invades muscularis propria
T2a: superficial muscularis propria (inner half)
T2b: deep muscularis propria (outer half)
T3: invades perivesical tissue/fat
T3a: invades perivesical tissue/fat microscopically
T3b: invades perivesical tissue/fat macroscopically (extravesical mass)
T4: invades prostate, uterus, vagina, pelvic wall, abdominal wall
T4a: adjacent organs (uterus, ovaries, prostate stroma)
T4b: invades pelvic wall and/or abdominal wall
N and M for bladder cancer
Stages for TNM bladder cancer, 0a - IV b
CSS in high-grade dz:
Ranges 70-85% at 10 years
At time of TURBT, clinicians SHOULD document and perform cystoscopic exam of what? Additionally, they should perform what type of resection?
GUIDELINE STATEMENT 1
Entire urethra and bladder
Document tumor size, location, configuration, number, and mucosal abnormalities
GUIDELINE STATEMENT 2
A complete visual resection when feasable
Define low risk NMIBC
Low risk
LG solitary Ta < 3 cm
PUNLMP
Define intermediate risk NMIBC:
Intermediate risk:
Recurrent w/in 1 year, LG Ta
Solitary LG Ta > 3 cm
LG Ta, multifocal
HG Ta, < 3 cm
LG T1
Define high risk NMIBC:
HG T1
Any recurrent, HG Ta
HG Ta, > 3 cm (or multifocal)
Any CIS
Any BCG failure in HG pt
Any variant histology
Any LVI
Any HG prostatic involvement
Besides resection/cysto, what else SHOULD be performed as part of initial workup of bladder cancer patient?
GUIDELINE STATEMENT 3
Upper tract imaging (tumors <5%)
RGP, CT/MRI urogram, US
Risk stratified and generally w/in 6 mo of dx and every 1-2years (high risk)
What SHOULD a clinician consider in a pt with NMIBC and normal cystoscopy and positive cytology?
GUIDELINE STATEMENT 4
prostatic urethral biopsies and upper tract imaging
consider enhanced techniques (blue light), URS, random bladder bx
At each occurrence/recurrence, clinicians SHOULD:
GUIDELINE STATEMENT 5
assign clinical stage and classify risk category
In variant histology results, what is recommend:
GUIDELINE STATEMENT 6
review of pathology by experience GU pathologist
(micro-papillary, plamacytoid, nested, neuroendocrine, sarcomatoid)
extensive squamous or glandular differentiation or presence of LVI
If pt with variant histology (presumed non-invasive) considering bladder preservation, the clinician SHOULD perform and offer?
GUIDELINE STATEMENT 7
perform re-staging TURBT in 4-6 weeks
*r/o MIBC (high rate upstaging)
GUIDELINE STATEMENT 8
Offer radical cystectomy
Is there a role of urinary biomarkers for surveillance of NMIBC?
GUIDELINE STATEMETN 9
NOT in lieu of cysto
cytology is mainstay despite drawbacks
5 markers are FDA approved
GUIDELINE STATEMENT 10
low risk cancer and normal cysto, do not routinely use biomarker or cytology for surveillance
When are urine biomarkers recommended?
GUIDELINE STATEMENT 11
In NMIBC to assess response to BCG (UroVysion FISH) and to adjudicate equivocal cytology (UroVysion FISH and ImmunoCyt)
What instances get a repeat TURBT?
GUIDELINE STATEMENT 12
incomplete initial resection (not all visible tumor)
GUIDELINE STATEMENT 13
high risk, HG Ta, consider repeat in 6 weeks (residual tumor up to 50% time, 15% upstaged)
GUIDELINE STATEMENT 14
T1, of primary tumor site to include muscularis propria in 6 weeks (upstage in 40-50% w/o muscle and 15-20% with muscle, improved BCG response, tx with mitomycin → lower recurrence and progression)
In patient with suspected or known low- or intermediate risk bladder cancer, clinicians SHOULD:
GUIDELINE STATEMENT 15
administration of single post operative chemo (Gemzar 2g/100mL, mitomycin)
GUIDELINE STATEMENT 16
Low-risk → NO intravesical induction
GUIDELINE STATEMENT 17
Intermediate-risk → consider 6 week induction (such as mitomycin, gemcitabine, epirubicin, or docetaxel in leiu of BCG due to shortage)
In high-risk newly dx CIS, HG T1 or high risk Ta, what SHOULD be done:
GUIDELINE STATEMENT 18
Induction 6 week BCG
**If not available, these patients and other high-risk patients may be given a reduced 1/2 to 1/3 dose, if feasible, if no supply, omit maintenance or limit to 1 year
Gemcitabine, epirubicin, docetaxel, valrubicin, mitomycin, or sequential gemcitabine/docetaxel or gemcitabine/mitomycin may also be considered with an induction and possible maintenance.
Insufficient evidence to support strain, strength, or combo BCG tx
In intermediate-risk pt who responds to induction, may utilize:
GUIDELINE STATEMENT 19
Maintenance
Monthly for 6-12 mo
GUIDELINE STATEMENT 20
if given BCG and responds → maintenance 1 year (if supply)
In high-risk patients who respond to BCG, maintenance:
GUIDELINE STATMENT 21
Continue for 3 years
3 weekly installments at 3, 6, 12, 18, 24, 30, 36 mo
For persistent or recurrent disease or positive cytology following intravesical therapy, clinicians SHOULD consider:
GUIDELINE STATEMENT 22
prostatic urethral biopsy and upper tract evaluation before repeat intravesical therapy
*UC especially CIS considered “field-change” dz, entire urothelium at risk
Tumor recurrence involves prostatic urethra in 24-30% of NMIBC
Blue light cysto improves CIS detection by 20-40%
Pt with persistent Ta or CIS dz after induction intravesical BCG SHOULD be offered:
GUIDELINE STATEMENT 23
A second course of induction
In a patient with persistent/recurrent HG T1 dz after single induction of BCG, SHOULD be offered:
GUIDELINE STATEMENT 24
Radical Cystectomy if fit for surgery
When is an additional course of BCG not appropriate?
GUIDELINE STATEMENT 25
Intolerance of BCG
Documented recurrence on TURBT of HG dz or CIS w/in 6 mo of 2 courses BCG or induction + maintenance
What treatment can be offered for persistent or recurrent intermediate- or high-risk NMIBC w/in 12 months of completion of adequate BCG therapy?
GUIDELINE STATMENT 26
BCG (2 inductions or induction + maintenance)
radical cystectomy
unwilling or unfit for cystectomy → alternative intravesical agent (valrubicin, gemcitabine, docetaxel, combo)
clinical trials
Systemic immunotherapy with pembrolizumab for CIS
Outline role of cystectomy in NMIBC:
GUIDELINE STATEMENT 27
Ta low- or intermediate- risk dz → DO NOT perform RC until bladder sparing modalities have failed
GUIDELINE STATEMENT 28
Persistent HG T1 on repeat resection, or T1 tumors with CIS, LVI, variant → offer RC
GUIDELINE STATMENT 29
High-risk with persistent or recurrent dz w/in 12 mo of appropriate BCG → offer RC
What is the role of enhanced cystoscopy?
GUIDELINE STATEMENT 30
offer blue light cysto at time of TURBT if available → increase detection, decrease recurrence
Hexaminolevulinate (HAL) FDA approved for BLC
GUIDELINE STATEMENT 31
Consider use of narrow band imaging (NBI) to increase detection and decrease recurrence
Discuss surveillance protocol for low- risk patient:
Reminder: LG solitary Ta < 3 cm, PUNLMP
GUIDELINE STATEMENT 32
first cysto in 3-4 mo
GUIDELINE STATEMENT 33
after first surveillance cysto neg, repeat cysto in 6-9 mo, then annually thereafter, after 5 year in absence of recurrence → SDM
GUIDELINE STATEMENT 34
Asx low-risk patient, should Not perform routine surveillance upper tract imaging
GUIDELINE STATEMENT 35
LG Ta and noted sub-cm papillary tumor (s), may consider in-office fulguration
Describe surveillance protocol for intermediate risk dz:
Reminder: Recurrent w/in 1 year LG Ta, Solitary LG Ta > 3 cm, LG Ta, multifocal, HG Ta, < 3 cm, or LG T1
GUIDELINE STATEMENT 36
first surveillance cysto 3 mo
if neg, subsequent cysto and cytology every 3-6 mo for 2 years, q 6-12 mo for years 3-4, then annually after 5 years
GUIDELINE STATEMENT 38
intermediate- or high-risk patients should consider upper tract surveillance imaging at 1-2 year intervals
Describe high-risk surveillance protocol:
Reminder: HG T1, Any recurrent, HG Ta, HG Ta, > 3 cm (or multifocal), Any CIS, Any BCG failure in HG pt, Any variant histology, Any LVI, Any HG prostatic involvement
GUIDELINE STATEMENT 37
first surveillance 3 mo
cystoscopy and cytology q 3-4 mo for 2 years, q 6 mo for years 3-4, and then annually
GUIDELINE STATEMENT 38
intermediate- or high-risk patients should consider upper tract surveillance imaging at 1-2 year intervals
Recurrence rates of bladder cancer by stage:
pT2 → 20-30%
pT3 → 40%
pT2 → 70% (node pos dz)
What is part of workup for suspected MIBC:
GUIDELINE STATEMENT 1
H&P, EUA at time of TURBT
GUIDELINE STATEMENT 2
full staging evaluation → CXR/Chest CT, A/P cross sectional imaging (IV contrast if possible)
Labs CBC, CMP (LFT, ALP, renal function)
Goals of pre-operative imaging in MIBC:
- determine feasibility and safety of removing the bladder
- presence of pelvic LAN
- presence of hydronephrosis
- presence of upper tract dz
- possible visceral/distant mets